Cory Kasimov
Stock Analyst at Evercore ISI Group
(4.33)
# 354
Out of 4,900 analysts
75
Total ratings
57.69%
Success rate
16.61%
Average return
Main Sectors:
Stocks Rated by Cory Kasimov
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| XENE Xenon Pharmaceuticals | Initiates: Outperform | $55 | $31.47 | +74.77% | 1 | May 14, 2025 | |
| MRNA Moderna | Maintains: In-Line | $50 → $32 | $31.58 | +1.33% | 6 | May 2, 2025 | |
| NBIX Neurocrine Biosciences | Maintains: Outperform | $190 → $185 | $131.24 | +40.96% | 2 | Apr 24, 2025 | |
| SMMT Summit Therapeutics | Initiates: Outperform | $30 | $24.36 | +23.15% | 1 | Mar 12, 2025 | |
| BBIO BridgeBio Pharma | Maintains: Outperform | $45 → $50 | $46.97 | +6.46% | 3 | Dec 23, 2024 | |
| EWTX Edgewise Therapeutics | Maintains: Outperform | $45 → $50 | $13.38 | +273.69% | 2 | Dec 17, 2024 | |
| BNTX BioNTech SE | Upgrades: Outperform | $110 → $125 | $110.65 | +12.97% | 4 | Nov 19, 2024 | |
| BMRN BioMarin Pharmaceutical | Maintains: Outperform | $115 → $105 | $56.62 | +85.45% | 12 | Oct 30, 2024 | |
| REGN Regeneron Pharmaceuticals | Maintains: Outperform | $1,250 → $1,175 | $547.96 | +114.43% | 5 | Oct 24, 2024 | |
| ACLX Arcellx | Initiates: Outperform | $85 | $68.14 | +24.74% | 1 | May 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $84 → $88 | $27.20 | +223.53% | 6 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $324 → $276 | $127.50 | +116.47% | 4 | Dec 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $35 | $4.18 | +737.32% | 1 | Mar 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $225 → $232 | $292.51 | -20.69% | 5 | Jul 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $68.25 | - | 5 | May 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $109.06 | - | 5 | May 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $25 → $21 | $28.85 | -27.21% | 4 | Feb 14, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $83 → $23 | $3.46 | +564.74% | 6 | Nov 2, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $310 → $250 | $10.44 | +2,295.78% | 1 | Feb 14, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $15 → $10 | $1.15 | +769.57% | 1 | Feb 14, 2018 |
Xenon Pharmaceuticals
May 14, 2025
Initiates: Outperform
Price Target: $55
Current: $31.47
Upside: +74.77%
Moderna
May 2, 2025
Maintains: In-Line
Price Target: $50 → $32
Current: $31.58
Upside: +1.33%
Neurocrine Biosciences
Apr 24, 2025
Maintains: Outperform
Price Target: $190 → $185
Current: $131.24
Upside: +40.96%
Summit Therapeutics
Mar 12, 2025
Initiates: Outperform
Price Target: $30
Current: $24.36
Upside: +23.15%
BridgeBio Pharma
Dec 23, 2024
Maintains: Outperform
Price Target: $45 → $50
Current: $46.97
Upside: +6.46%
Edgewise Therapeutics
Dec 17, 2024
Maintains: Outperform
Price Target: $45 → $50
Current: $13.38
Upside: +273.69%
BioNTech SE
Nov 19, 2024
Upgrades: Outperform
Price Target: $110 → $125
Current: $110.65
Upside: +12.97%
BioMarin Pharmaceutical
Oct 30, 2024
Maintains: Outperform
Price Target: $115 → $105
Current: $56.62
Upside: +85.45%
Regeneron Pharmaceuticals
Oct 24, 2024
Maintains: Outperform
Price Target: $1,250 → $1,175
Current: $547.96
Upside: +114.43%
Arcellx
May 14, 2024
Initiates: Outperform
Price Target: $85
Current: $68.14
Upside: +24.74%
Feb 27, 2024
Maintains: Overweight
Price Target: $84 → $88
Current: $27.20
Upside: +223.53%
Dec 21, 2021
Maintains: Neutral
Price Target: $324 → $276
Current: $127.50
Upside: +116.47%
Mar 1, 2021
Initiates: Neutral
Price Target: $35
Current: $4.18
Upside: +737.32%
Jul 29, 2020
Maintains: Neutral
Price Target: $225 → $232
Current: $292.51
Upside: -20.69%
May 6, 2020
Downgrades: Neutral
Price Target: n/a
Current: $68.25
Upside: -
May 1, 2020
Downgrades: Neutral
Price Target: n/a
Current: $109.06
Upside: -
Feb 14, 2020
Downgrades: Neutral
Price Target: $25 → $21
Current: $28.85
Upside: -27.21%
Nov 2, 2018
Maintains: Underweight
Price Target: $83 → $23
Current: $3.46
Upside: +564.74%
Feb 14, 2018
Maintains: Neutral
Price Target: $310 → $250
Current: $10.44
Upside: +2,295.78%
Feb 14, 2018
Maintains: Underweight
Price Target: $15 → $10
Current: $1.15
Upside: +769.57%